HaruyaMKanoS. A new look at the corporate capability of personalized medicine development in the pharmaceutical industry. R&D Manage2015; 45(1): 94–103.
2.
DiestreLRajagopalanNDuttaS. Constraints in acquiring and utilizing directors' experience: An empirical study of new-market entry in the pharmaceutical industry. Strat Manage J2015; 36(3): 339–359.
3.
MatikainenMTerhoHMatikainenE. Effective implementation of relationship orientation in new product launches. Ind Market Manage2015; 45: 35–46.
4.
HansenKRNGrunowM. Planning operations before market launch for balancing time-to-market and risks in pharmaceutical supply chains. Int J Prod Econ2015; 161: 129–139.
5.
ManiSLuoX. Product alliances, alliance networks, and shareholder value: Evidence from the biopharmaceutical industry. Int J Res Market2015; 32(1): 9–22.
6.
RaoSK. Trends in market access for specialty biologics: Challenges & promises. J Comm Biotechnol2015; 21(2): 10–19.
